Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





AI to Revolutionize Testing and Treatment of Lyme Disease

By LabMedica International staff writers
Posted on 01 Aug 2025

Every year, over 475,000 individuals in the U. More...

S. are diagnosed with Lyme disease — a number expected to rise as climate change broadens the regions where ticks thrive. While the disease is highly treatable with antibiotics if detected early, the current standard test, known as two-tier serology, correctly identifies early Lyme in only about 30% of cases. This low accuracy represents a critical gap, as more than half of those not diagnosed or treated within the first few weeks of infection go on to suffer long-term issues like fatigue, arthritis, and neurocognitive impairments. Now, a new artificial intelligence (AI)-enhanced blood test unveiled at ADLM 2025 offers earlier and more reliable detection, potentially leading to significantly better patient outcomes. Another study presented at the show illustrates how generative AI tools can support adolescents in accessing helpful medical information. Together, these developments demonstrate how AI, when responsibly applied, can have a meaningful impact on health outcomes in clinical laboratory medicine.

ACES Diagnostics (New Orleans, LA, USA) has introduced a new test that utilizes AI to significantly enhance Lyme disease detection. With sensitivity and specificity both exceeding 90%, the test ensures that 9 out of 10 patients receive accurate results, thereby improving chances of timely treatment and reducing the risk of chronic complications. The test builds on immunological research conducted in rhesus macaques — animals whose immune response closely resembles that of humans when infected with Lyme-causing bacteria. Based on this, the researchers developed a single-panel test that screens for 10 different proteins (antigens), streamlining diagnosis compared to the traditional method that may require up to four separate tests. The ACES team further validated the test using blood samples from 123 Lyme-positive and 197 Lyme-negative individuals, integrating machine learning to recognize distinct immune response patterns. The final algorithm demonstrated robust performance across all stages of the disease, detecting over 90% of early-stage cases — a sharp contrast to the 27% accuracy rate seen with the standard two-tier approach. Cost-effective and compatible with widely available laboratory systems, the test is anticipated to enter the commercial market by late 2026.

In the second study presented at ADLM 2025, researchers examined how Medicine-GPT — a specialized ChatGPT-based model developed by physicians — can aid teenagers in finding reliable health information. Adolescents, known for their early adoption of technology, often turn to the internet for answers to sensitive health concerns. The study, conducted by Weill Cornell Medicine (New York, NY, USA), analyzed over 100 diagnostic and lab-related queries posted by users aged 10–19 on Reddit’s “Ask Doctors” forum, selecting the top-ranked posts based on user engagement. The team then compared the performance of Medicine-GPT with that of the general ChatGPT-4 model. While both models maintained full factual accuracy, Medicine-GPT outshone its predecessor in several categories: 66.6% for completeness, 60% for reasoning, and 46.6% for helpfulness — compared to 20%, 33.3%, and 23.3%, respectively, for ChatGPT-4. On clarity, Medicine-GPT also scored higher (80%) than ChatGPT-4 (70%). However, the study also identified a concern: these AI tools can sometimes unintentionally overwhelm users, particularly adolescents, by including rare or fatal diagnoses that may heighten anxiety.

“This highlights the need for future AI tools to not only be medically accurate, but also context-aware, user-sensitive, and aligned with how clinicians communicate,” said Austin Jin, a high school research intern at Weill Cornell Medicine. “Rather than discouraging use, providers can guide adolescents on how to use these tools responsibly, emphasizing that AI … should never replace professional medical advice or personalized evaluation.”

Related Links:
ACES Diagnostics
Weill Cornell Medicine


Gold Member
Serological Pipets
INTEGRA Serological Pipets
Collection and Transport System
PurSafe Plus®
New
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
New
Rapid Molecular Testing Device
FlashDetect Flash10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Over 100 new epigenetic biomarkers may help predict cardiovascular disease risk (Photo courtesy of 123RF)

Routine Blood Draws Could Detect Epigenetic Biomarkers for Predicting Cardiovascular Disease Risk

Cardiovascular disease is a leading cause of death worldwide, yet predicting individual risk remains a persistent challenge. Traditional risk factors, while useful, do not fully capture biological changes... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.